FDA Approved: LAMICTAL ODT — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for LAMICTAL ODT (lamotrigine) submitted by GlaxoSmithKline, updating its regulatory status for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy

Drugs mentioned

• LAMICTAL ODT (lamotrigine)

Snippet

SUPPL AP for LAMICTAL ODT (LAMOTRIGINE)